Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease | Small Molecules | News Channels – PipelineReview.com

Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease | Small Molecules | News Channels – PipelineReview.com
Source: Google NewsPublished on 2022-06-23